Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SlimBiome is a patented weight management ingredient developed by OptiBiotix Health PLC in collaboration with UK universities. It is a multi-component formulation consisting of glucomannan (a dietary fiber from konjac root), fructo-oligosaccharides (a prebiotic fiber), and chromium (a trace mineral). The product is designed to aid weight loss by promoting satiety through increased stomach viscosity and delayed gastric emptying, while also moderating blood glucose levels and supporting a healthy gut microbiome. It has been marketed both as a CE-marked Class IIa medical device (SlimBiome Medical) and as a dietary supplement (SlimBiome X3). Clinical studies indicate it can significantly reduce hunger and food cravings, leading to measurable weight loss of approximately 2kg over four weeks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SlimBiome.